Loretta Nastoupil, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the evolving treatment landscape of lymphoma, including recent data evaluating allogeneic CAR T-cells in the relapsed/refractory setting. Furthermore, the development of novel targeted agents such as tafasitamb, as evaluated in the Phase II L-MIND study (NCT02399085), represents an exciting approach in the lymphoma field. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).